Risultati per: FDA approva un nuovo trattamento per l’emicrania

Objectives
US FDA and EMA allow facilitated regulatory pathways to expedite access to new treatments. Limited supportive data may result in major postapproval variations. In Israel, partly relying on Food and Drug Administration (FDA) and European Medicines Agency (EMA), clinical data are reviewed independently by the Advisory Committee of Drug Registration (ACDR). In this study, the correlation between the number of discussions at the ACDR and major postapproval variations is examined.

Design
This is an observational retrospective comparative cohort study.

Setting
Applications with FDA and/or EMA approval at time of assessment in Israel were included. The timeframe was chosen to allow a minimum of 3 years of postmarketing approval experience for potential major label variations. Data regarding the number of discussions at ACDR were extracted from protocols. Data on postapproval major variations were extracted from the FDA and EMA websites.

Results
Between 2014 and 2016, 226 (176 drugs) applications, met the study criteria. 198 (87.6%) and 28 (12.4%) were approved following single and multiple discussions, respectively. A major postapproval variation was recorded in 129 (65.2%) compared with 23 (82.1%) applications approved following single and multiple discussions, respectively (p=0.002). Increased risk for major variation was found for medicines approved following multiple discussions (HR=1.98, 95% CI: 1.26 to 3.09) with a median time of 1.2 years, applications approved based on phase II trials (HR=2.58, 95% CI: 1.72 to 3.87), surrogate endpoints (HR=1.99, 95% CI: 1.44 to 2.74) and oncologic indications (HR=2.48, 95% CI: 1.78 to 3.45).

Conclusions
Multiple ACDR discussions associated with limited supportive data are predictive for major postapproval variations. Moreover, our findings demonstrate that approval by the FDA and/or EMA does not pave the way to automatic approval in Israel. In a substantial per cent of the cases, submission of the same clinical data resulted in different safety and efficacy considerations, requiring additional supporting data in some cases or even rejection of the application in others.

Meeting dal 10 al 12 maggio all’Università La Sapienza

After authorizing Makena, a hydroxyprogesterone caproate injection, under an accelerated approval pathway in 2011, the US Food and Drug Administration (FDA) has pulled approval for the drug. “[T]he touchstone of FDA drug approval is a favorable benefit-risk assessment,” FDA Commissioner Robert M. Califf, MD, said in a statement. “[W]ithout that favorable assessment, the drug should not have the status of being FDA-approved.”

Narcan, a 4-mg naloxone hydrochloride nasal spray that reverses the effects of opioid overdose, will soon be available for purchase without a prescription, the US Food and Drug Administration (FDA) announced in a statement.

New England Journal of Medicine, Ahead of Print.

Dense breasts place people at higher risk of breast cancer but also make it harder to pick up abnormalities on x-rays. A new rule by the US Food and Drug Administration (FDA) standardizes the information patients receive from their mammogram providers about their breast density. It also requires language prompting patients—particularly those with dense breasts—to talk in greater depth with their physicians about their results and whether additional imaging makes sense.

The US Food and Drug Administration (FDA) recently approved trofinetide, an oral solution marketed as Daybue, for the treatment of Rett syndrome, a rare genetic disorder that alters brain development, among adults and children aged 2 years or older. Common adverse effects of the twice-daily oral drug include diarrhea and vomiting, an FDA statement noted.

Rilevati in sangue bambini e teenager, legati a gravità cefalea

Rilevati in sangue bambini e teenager, legati a gravità cefalea

New England Journal of Medicine, Ahead of Print.

This cross-sectional study determines the frequency of and rationale for US Food and Drug Administration (FDA) approval of drugs not meeting pivotal trial primary efficacy end points.

This cross-sectional study evaluates regulatory decisions and health technology assessments in Australia, Canada, and the UK regarding new drugs approved by the US Food and Drug Administration in 2017 through 2020, as well as estimates the US cost per patient per year for drugs receiving negative recommendations.

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Diversi disturbi seguono ritmi circadiani o sono stagionali

Rischio doppio di soffrirne per i giovani pazienti emicranici